Society of Gynecologic Oncology

The Foundation for Women's Cancer Named "Partner-of-Choice" by The Institute for Surgical Excellence Receiving $155,555 to Drive Change in Women's Cancer

Retrieved on: 
Thursday, April 18, 2024
Education, SGO, Society, Cancer, Cure, Learning, Social media, Machine learning, Surgeon, Gynecologic Oncology (journal), Research, Artificial intelligence, Ginger, Celebration, Patient, Society of Gynecologic Oncology, Physician, Movement, Oncology nursing, FWC, Student, FACOG, Knowledge

CHICAGO, April 18, 2024 /PRNewswire-PRWeb/ -- The Foundation for Women's Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), launched its signature annual fundraising campaign, Move4Her, last month in San Diego in conjunction with the Institute for Surgical Excellence (ISE) Celebration of Champions Day (March 14), FWC Patient & Advocate Education Forum (March 15), and SGO Annual Meeting on Women's Cancer (March 16-18).

Key Points: 
  • "It was spectacular to bring so many people together for a common cause, to share knowledge and build community.
  • The resulting donation from the ISE to the FWC will help meet critical needs in education, awareness, and grants to further research in women's cancer."
  • "It was spectacular to bring so many people together for a common cause, to share knowledge and build community.
  • "There are so many exciting medical breakthroughs happening that will improve the lives of people faced with a cancer diagnosis.

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

Retrieved on: 
Tuesday, March 12, 2024
Research, Women, Genetics, Clinical Trials, Biotechnology, Health, Consumer, Science, Oncology, Ovarian cancer, Patient, DNA, SGO, MD, Abstract, NTRA, Breast cancer, MRD, Gynecologic Oncology (journal), Medicare, Society of Gynecologic Oncology, Birth control

A total of seven abstracts will be presented, including two oral presentations and five poster presentations.

Key Points: 
  • A total of seven abstracts will be presented, including two oral presentations and five poster presentations.
  • The presentations will feature new data highlighting Signatera’s predictive and prognostic utility in ovarian cancer and other gynecologic malignancies.
  • “On the heels of receiving Medicare coverage for Signatera in ovarian cancer and for breast cancer in the neoadjuvant setting, we are thrilled to share new Signatera and Empower data with the gynecologic oncology community,” said Adam ElNaggar, MD, medical director of oncology at Natera.
  • “We believe this momentum is indicative of the growing clinical value our tests provide for patients across the continuum of gynecologic cancer care, and demonstrate our continued leadership in MRD.”
    Below is the full list of Signatera and Empower data presentations at the SGO Annual Meeting.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Retrieved on: 
Tuesday, February 20, 2024
Oncology, FDA, Health, General Health, Pharmaceutical, Biotechnology, MSD, Carboplatin, MRK, Society of Gynecologic Oncology, Food, PDUFA, Risk, Cancer, Gynecologic Oncology (journal), Death, Paclitaxel, SGO, Patient, Pharmaceutical industry

The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.
  • The sBLA is based on data from the Phase 3 NRG-GY018 trial.
  • Health authorities in Israel, Canada, Australia, Singapore and Brazil will review this application as part of Project Orbis.
  • In endometrial cancer, Merck is evaluating KEYTRUDA in the first-line setting for advanced or recurrent disease that is dMMR (KEYNOTE-C93/ENGOT-en15/GOG-3064) and in the adjuvant setting (KEYNOTE-B21/ENGOT-en11/GOG-3053).

INTEGRATED ONCOLOGY NETWORK ANNOUNCES cCARE EXPANSION WITH SPECIALTY CLINIC IN RIVERSIDE, CALIFORNIA

Retrieved on: 
Thursday, December 7, 2023
ION, Medical director, Gynecologic Oncology (journal), University, Patient, American College, Society of Gynecologic Oncology, Partnership, Society, Hospital, Nursing, MD

NASHVILLE, Tenn., Dec. 7, 2023 /PRNewswire/ -- Integrated Oncology Network (ION), with California Cancer Associates for Research & Excellence (cCARE) is thrilled to announce the opening of its newest clinic, dedicated to advancing gynecologic oncology services in Riverside, California. This expansion marks a significant advancement into a new community and market, reinforcing our commitment to providing the highest level of comprehensive and specialized care.

Key Points: 
  • Expanding Community Cancer Care with Gynecologic Oncology Services; Welcoming Dr. Valerie Galvan-Turner
    NASHVILLE, Tenn., Dec. 7, 2023 /PRNewswire/ -- Integrated Oncology Network (ION), with California Cancer Associates for Research & Excellence (cCARE) is thrilled to announce the opening of its newest clinic, dedicated to advancing gynecologic oncology services in Riverside, California.
  • The cCARE Riverside clinic is now open, welcoming patients seeking specialized gynecologic oncology care!
  • Barry Tanner, CEO of Integrated Oncology Network, emphasized the strategic importance of this expansion: "The launch of cCARE's specialty oncology clinic with gynecologic oncology services underscores our mission to make a positive impact on the communities and lives of patients we serve nationwide.
  • The cCARE Riverside clinic is now open, welcoming patients seeking specialized gynecologic oncology care.

Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer

Retrieved on: 
Thursday, November 16, 2023
Orbis, Carboplatin, Paclitaxel, Priority review, Woman, Oncology nursing, Health Canada, Annual general meeting, SGO, Policy, Food, Platinum, Gynecologic Oncology (journal), US Foods, ESMO, Patient, Society of Gynecologic Oncology, Part, FDA, GOC, Endometrial cancer, Health, Standard of care, Cancer, CCSN, Survival, Partnership, Oncology, Society, MSI-H, Birth control, Pharmaceutical industry, Dostarlimab, MISSISSAUGA

Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.

Key Points: 
  • Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.
  • [1]
    "Today's approval supports our ambition for Jemperli to advance the standard of care for Canadian adult patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer," said Marni Freeman, Country Medical Director at GSK Canada.
  • "This expanded approval of Jemperli offers a new care option to healthcare professionals treating this patient population with high unmet need."
  • "The CCSN is pleased to see a newly approved innovative treatment option for patients in Canada.

Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Retrieved on: 
Monday, July 31, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Orbis, GSK, Priority review, US Foods, Risk, Prescription Drug User Fee Act, Radiation, Society, SGO, Senior, Diarrhea, Society of Gynecologic Oncology, The New England Journal of Medicine, ESMO, European Medicines Agency, Clinical trial, Paclitaxel, Hope, Gynecologic Oncology (journal), Part, Carboplatin, Hypothyroidism, European Society for Medical Oncology, PFS, Rash, Hypertension, GSK plc, Endometrial cancer, HIV disease progression rates, MD, Patient, Division, FORCE, Annual general meeting, Washington University School of Medicine, United Kingdom, European Society of Gynaecological Oncology, ITT, Death, III, News, Food, Safety, Pharmaceutical industry, Dostarlimab

Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Key Points: 
  • Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
  • Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression.
  • These results and today’s approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy.”
    With this approval, Jemperli is now indicated earlier in treatment in combination with chemotherapy for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
  • The most common treatment-emergent adverse events (≥ 20%) in patients receiving Jemperli plus chemotherapy were rash, diarrhea, hypothyroidism and hypertension.

Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023
Health, Pharmaceutical, CIN, Artesunate, Society, Therapy, Clinical trial, NDA, Woman, Society of Gynecologic Oncology, Cervical intraepithelial neoplasia, Research, Candidiasis, E7, Discovery, E6, Gynaecology, HPV, Growth, Intraepithelial neoplasia, III, Inovio Pharmaceuticals, Human papillomavirus infection, News, Birth control, Pharmaceutical industry, Gynecologic Oncology (journal), Cervical, Phase

The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.
  • This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs.
  • The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e.

Move4Her Returns Empowering Participants in the Fight to Eradicate Gynecologic Cancers

Retrieved on: 
Thursday, June 15, 2023
Society, SGO, Education, Vulvar cancer, FWC, National Press Club (United States), Press club, Gynecologic Oncology (journal), Research, Movement, EMLL 55th Anniversary Show, Organization, Society of Gynecologic Oncology, MD, Cancer, Diagnosis, Health, Message, Birth control

CHICAGO, June 15, 2023 /PRNewswire/ -- The Foundation for Women's Cancer (FWC) is pleased to announce the return of Move4Her, now bigger and better than ever! Embarking on its fourth consecutive year, Move4Her stands at the forefront of the FWC's mission to power research, awareness and education surrounding the five gynecologic (gyn) cancers – cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer.

Key Points: 
  • Embarking on its fourth consecutive year, Move4Her stands at the forefront of the FWC's mission to power research, awareness and education surrounding the five gynecologic (gyn) cancers – cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer.
  • Move4Her encourages participants to dedicate five minutes each day to their fitness and fundraising mission.
  • Taking steps to protect your health, and to connect with others by sharing stories and experiences, Move4Her participants will power a much-needed movement.
  • Throughout the year new tools and resources will be released to support individuals, teams and local organizations participating in Move4Her.

Burjeel Medical City Launches Advanced Gynecology Institute to Offer Complex Care Solutions for Women

Retrieved on: 
Tuesday, May 23, 2023
Oncology, Health, Consumer, Hospitals, Women, General Health, Endometriosis, AGI, Specialist, Obstetrics, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Consultant, Society of Gynecologic Oncology, Quality of life, Woman, Multimedia, Government, Patient, Gynaecology, Gynecologic cancer disparities in the United States, Nursing, State, Medical City

Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages.

Key Points: 
  • Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages.
  • Three specialized clinics of the hospital - Gynecological Oncology, IFEM Endo Middle East Clinic, and Complex Gynecology Care - will come under AGI.
  • Dr. Maitha Bint Salem Al Shamsi, Minister of State, UAE Government, inaugurating Advanced Gynecology Institute at Burjeel Medical City (Photo: AETOSWire)
    Prof. Horace Roman, a renowned endometriosis surgeon and founding member of IFEM Endo, will be heading the institute.
  • “The institute showcases our commitment to excellence and cements our position as a leader in complex care.

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

Retrieved on: 
Friday, April 28, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Biologics license application, Capital expenditure, Society, SGO, ASH, Senior, Progression-free survival, Marketing, European Medicines Agency, Survival, Clinical trial, Cancer, Gynecologic Oncology (journal), György Enyedi (geographer), Society of Gynecologic Oncology, NSCLC, Lung cancer, PFS, Mirvetuximab soravtansine, Gilead, Eli Lilly, EMA, Acute myeloid leukemia, PROC, AML, Azacitidine, PIN, Huadong Medicine, Pharmakon—Danish College of Pharmacy Practice, Patient, National Medical Products Administration, Annual general meeting, ImmunoGen, Vertex Pharmaceuticals, ADC, Spacecraft, MAA, Research, FDA, Ovarian cancer, LP, BLA, NMPA, Medicine, Vaccine, Management, Pharmaceutical industry, Mobile phone, Vertex

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
  • Research and development expenses rose to $51.6 million for the quarter ended March 31, 2023 compared to $44.3 million for the quarter ended March 31, 2022.
  • Selling, general and administrative expenses were $40.0 million for the quarter ended March 31, 2023 compared to $16.6 million for the quarter ended March 31, 2022.
  • ImmunoGen had $201.2 million in cash and cash equivalents as of March 31, 2023, compared with $275.1 million as of December 31, 2022.